Policy Developments - The National Healthcare Security Administration (NHSA) announced that by the end of 2025, all coordinated areas in the country must implement instant settlement for medical insurance funds [2] - By the end of 2026, instant settlement funds should account for over 80% of the local medical insurance fund's monthly settlement funds, covering various medical expenses [2] Industry Developments - Jiangxi Province is promoting the development of modern seed industry for traditional Chinese medicine, focusing on the protection of medicinal material resources and the establishment of breeding bases [3] - The company Jiuzhoutong received approval for the market launch of the chemical raw material drug, Glycopyrrolate, which will enhance its product line and market competitiveness [5] - Sichuan Shuangma's subsidiary obtained approval for the chemical raw material drug, Leuprolide Acetate, further strengthening its competitive advantage in the domestic raw material drug sector [6] Financial Reports - Guobang Pharmaceutical reported a 23.17% year-on-year increase in net profit for Q3, despite a 5.39% decline in revenue [8] Investment Activities - OxTium Technology completed several million yuan in angel+ round financing, led by Sequoia China Seed Fund [11] Clinical Research - Eli Lilly announced positive results from two Phase 3 clinical trials for orforglipron, showing significant improvements in blood sugar control and weight loss for type 2 diabetes patients [14] Shareholder Actions - Kangtai Medical announced that major shareholder Wang Guili reduced her holdings by 4.24 million shares, decreasing her ownership to 8.95% [17]

Core Viewpoint - The company Kyushu Tong (600998.SH) announced that its subsidiary Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd. received approval from the National Medical Products Administration for the marketing application of Glycopyrrolate, a quaternary ammonium anticholinergic drug [1] Group 1: Product Approval - The approval notification for Glycopyrrolate was issued on October 16, 2025 [1] - Glycopyrrolate is indicated for conditions such as gastric and duodenal ulcers, chronic gastritis, and for maintenance treatment in adults with chronic obstructive pulmonary disease (COPD) [1] Group 2: Drug Mechanism and Applications - Glycopyrrolate selectively acts on the gastrointestinal tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] - The drug specifically binds to and inhibits the M3 acetylcholine receptors in bronchial smooth muscle, leading to airway dilation [1]

Core Viewpoint - The company Kyushu Tong (600998.SH) announced that its subsidiary Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd. received approval from the National Medical Products Administration for the marketing application of Glycopyrrolate, a quaternary ammonium anticholinergic drug [1] Group 1: Product Information - Glycopyrrolate selectively acts on the gastrointestinal tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] - The drug specifically binds to and inhibits the M3 acetylcholine receptors in bronchial smooth muscle, leading to airway dilation [1] - Glycopyrrolate is indicated for the treatment of gastric and duodenal ulcers, chronic gastritis, and for maintenance bronchial dilation therapy in adults with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema [1]

证券代码：600998 证券简称：九州通 公告编号：临 2025-071 九州通医药集团股份有限公司 关于子公司获得化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 九州通医药集团股份有限公司（以下简称"公司"或"九州通"）控股子公 司北京京丰制药（山东）有限公司（以下简称"山东京丰"）于 2025 年 10 月 16 日收到国家药品监督管理局核准签发的《化学原料药上市申请批准通知书》，批 准格隆溴铵上市申请。现将相关情况公告如下： 一、上市申请批准通知书主要信息 化学原料药名称：格隆溴铵 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。 二、药品其他相关情况 格隆溴铵是一种季铵类抗胆碱药，能选择性作用于消化道，有抑制胃液分泌 和调整胃肠蠕动的作用，也可特异性结合并抑制支气管平滑肌分布的 M3 型乙酰 胆碱受体，扩张气道。该药品可用于胃、十二指肠溃疡及慢性胃炎等，还可用于 成人慢性阻塞性肺疾病（包括慢性支气管炎和肺气肿）患者维持性支气管扩张 ...

Core Viewpoint - The approval of the listing application for Glycopyrrolate by the National Medical Products Administration marks a significant milestone for the company, enhancing its product portfolio in the pharmaceutical market [1] Group 1: Product Approval - The company's subsidiary, Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the approval notice for the listing application of Glycopyrrolate on October 16, 2025 [1] - Glycopyrrolate is a quaternary ammonium anticholinergic drug that selectively acts on the gastrointestinal tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] - The drug can specifically bind to and inhibit the M3 acetylcholine receptors in bronchial smooth muscle, leading to airway dilation [1] Group 2: Product Forms - Glycopyrrolate is available in various formulations, including injection, inhalation powder, inhalation solution, oral solution, tablets, and a combination inhalation aerosol with Formoterol [1] - Some formulations, such as Glycopyrrolate injection and Glycopyrrolate/Formoterol inhalation aerosol, have been included in the medical insurance directory [1] Group 3: Sales Performance - In 2024, the hospital sales of Glycopyrrolate injection reached 53.5772 million yuan, representing a year-on-year growth of 38.29% [1] - In the first half of 2025, the hospital sales of Glycopyrrolate injection amounted to 37.407 million yuan, showing a significant year-on-year increase of 79.21% [1]

Core Viewpoint - The approval of the drug "Gelong Bromide" by the National Medical Products Administration marks a significant milestone for the company, indicating potential growth in the pharmaceutical market [1] Company Summary - The company, Jiuzhoutong, announced that its subsidiary, Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the approval for the listing application of Gelong Bromide on October 16, 2025 [1] - Gelong Bromide is a quaternary ammonium anticholinergic drug that selectively acts on the digestive tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] Product Summary - Gelong Bromide can be used for treating gastric and duodenal ulcers, chronic gastritis, and as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, including chronic bronchitis and emphysema [1] - The drug works by specifically binding to and inhibiting the M3 acetylcholine receptors distributed in bronchial smooth muscle, leading to airway dilation [1]

Core Viewpoint - The approval of the drug "Gelong Bromide" by the National Medical Products Administration marks a significant milestone for the company, enhancing its product portfolio in the pharmaceutical sector [1] Company Summary - The company, through its subsidiary Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the approval for the marketing application of Gelong Bromide on October 16, 2025 [1] - Gelong Bromide is a quaternary ammonium anticholinergic drug that selectively acts on the gastrointestinal tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] Product Details - Gelong Bromide can be used for treating gastric and duodenal ulcers, chronic gastritis, and as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, including chronic bronchitis and emphysema [1] - The drug specifically binds to and inhibits the M3 acetylcholine receptors in bronchial smooth muscle, leading to airway dilation [1]

Core Viewpoint - The approval of the listing application for Glycopyrrolate by the National Medical Products Administration is expected to positively impact the future development of the company's pharmaceutical industrial business and enhance its competitiveness in the active pharmaceutical ingredient market [1] Group 1: Company Developments - The company's subsidiary, Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the approval notice for the listing application of Glycopyrrolate on October 16, 2025 [1] - Glycopyrrolate is a quaternary ammonium anticholinergic drug used for treating gastric and duodenal ulcers, chronic gastritis, and for maintaining bronchial dilation in adult patients with chronic obstructive pulmonary disease [1] - The approval will enrich the company's product line and strengthen its market position in the active pharmaceutical ingredient sector [1]

Core Viewpoint - The announcement details the investment activities of Jiuzhoutong Pharmaceutical Group Co., Ltd. regarding entrusted financial management for the third quarter of 2025, highlighting the company's strategy to utilize idle funds for investment while ensuring operational liquidity and safety [2][4][12]. Investment Overview - The maximum balance of entrusted financial management for the third quarter of 2025 was 1.3 billion RMB, with a balance of 0 RMB at the end of the quarter [5][12]. - The company plans to use up to 4 billion RMB of idle funds for purchasing safe and liquid financial products, with individual investment periods not exceeding 12 months [2][8]. Investment Purpose - The purpose of the investment is to enhance the efficiency of fund utilization and generate investment returns without affecting the company's normal operational funding needs [4][12]. Funding Source - The funds for the entrusted financial management products in the third quarter of 2025 were sourced from the company's idle self-owned funds [6]. Investment Method - In the third quarter of 2025, the company used 5.4 billion RMB to purchase government bond reverse repos, with investment periods of 7 days and 5 days [7][8]. Risk Analysis and Control Measures - The investment scope primarily includes high-security, liquid, and capital-preserving financial products, with risks associated with market fluctuations and macroeconomic changes [3][9]. - The company has established risk management protocols, including selecting qualified financial institutions and maintaining oversight of investment activities [10]. Impact on the Company - The use of idle funds for entrusted financial management is designed to not disrupt the company's daily operations or main business activities, aiming to improve fund efficiency and yield better investment returns [12].

证券代码：600998 证券简称：九州通 公告编号：临 2025- 070 九州通医药集团股份有限公司 关于 2025 年第三季度委托理财情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 九州通医药集团股份有限公司（以下简称"公司"）于 2024 年 12 月 8 日和 2025 年 1 月 6 日分别召开第六届董事会第十一次会议和 2025 年第一次 临时股东会，审议通过了《关于公司 2025 年度使用临时闲置资金委托理财预 计的议案》，同意公司使用不超过人民币 40 亿元（余额）的临时闲置流动资 金适时购买安全性高、流动性较好的理财产品，单个理财产品的投资期限不 超过 12 个月（一般不超过 3 个月）。 特别风险提示 公司委托理财的投资范围主要是安全性高、流动性好的保本型理财产品，主 要风险包括市场波动风险、宏观经济形势及货币政策、财政政策等宏观政策发生 变化带来的系统性风险等，委托理财的实际收益存在不确定性，敬请广大投资者 注意投资风险。 1 一、投资情况概述 （一）投资目的 基本情况 | 投 ...